Dabrafenib + Trametinib in Patients w/rare BRAF V600E Mutated Solid Tumor (CDRB436IIC01) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to collect information about how well dabrafenib plus trametinib works in patients who have unresectable (cannot be removed by surgery) or metastatic BRAF V600E mutation positive solid tumors.
Unresectable or Metastatic BRAF V600E Mutation Positive Solid Tumors
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with unresectable or metastatic BRAF V600E mutation positive solid tumors
- Have not received dabrafenib-trametinib previously for your disease or have not received it for more than one year for any other malignancy
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
What is Involved?
If you choose to join this study, we will collect information related to your cancer and treatment and enter it into a database that we will keep indefinitely. This information will help us better understand how the drug combination works for people who have this rare mutation.
Study Details
